Dose-Escalating, Pilot Study to Assess the Safety, Tolerability, and Preliminary Efficacy of ALS-357 [betulinic acid] Topically Administered to Patients With Cutaneous Metastatic Melanoma

Trial Profile

Dose-Escalating, Pilot Study to Assess the Safety, Tolerability, and Preliminary Efficacy of ALS-357 [betulinic acid] Topically Administered to Patients With Cutaneous Metastatic Melanoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Betulinic acid (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions; Biomarker
  • Most Recent Events

    • 14 Apr 2009 New source identified and integrated (Robert H. Lurie Comprehensive Cancer Center, Northwestern University)
    • 19 Jun 2008 The expected completion date has been identified as Jun 2009, as reported by ClinicalTrials.gov.
    • 19 Jun 2008 Status changed from initiated to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top